Antares Pharma Inc (NASDAQ:ATRS) had its target price decreased by equities research analysts at HC Wainwright from $5.00 to $3.50 in a research note issued to investors on Monday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 60.55% from the stock’s current price.

ATRS has been the subject of a number of other reports. Vetr raised Antares Pharma from a “hold” rating to a “buy” rating and set a $3.42 price target for the company in a research note on Tuesday, July 18th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Antares Pharma in a research note on Friday, September 8th. Finally, ValuEngine cut Antares Pharma from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. One analyst has rated the stock with a sell rating, three have given a buy rating and two have issued a strong buy rating to the company. Antares Pharma currently has an average rating of “Buy” and a consensus target price of $4.04.

Antares Pharma (NASDAQ ATRS) opened at 2.18 on Monday. The stock has a 50 day moving average of $3.07 and a 200 day moving average of $2.98. The stock’s market capitalization is $340.97 million. Antares Pharma has a 52-week low of $1.41 and a 52-week high of $4.09.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. The company had revenue of $13.42 million during the quarter, compared to analysts’ expectations of $12.99 million. Antares Pharma had a negative return on equity of 27.89% and a negative net margin of 21.17%. On average, equities research analysts forecast that Antares Pharma will post ($0.11) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/23/hc-wainwright-cuts-antares-pharma-inc-atrs-price-target-to-3-50.html.

In other news, Director Thomas J. Garrity sold 30,000 shares of the company’s stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $3.50, for a total value of $105,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Leonard S. Jacob sold 230,000 shares of the company’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $4.05, for a total value of $931,500.00. The disclosure for this sale can be found here. Corporate insiders own 11.60% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Alliancebernstein L.P. bought a new stake in shares of Antares Pharma in the 2nd quarter valued at about $119,000. Legal & General Group Plc bought a new stake in Antares Pharma during the 2nd quarter worth approximately $120,000. MML Investors Services LLC increased its stake in Antares Pharma by 228.2% during the 2nd quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock worth $139,000 after purchasing an additional 30,000 shares in the last quarter. Credit Suisse AG bought a new stake in Antares Pharma during the 1st quarter worth approximately $146,000. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Antares Pharma during the 2nd quarter worth approximately $174,000. 36.77% of the stock is owned by institutional investors.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Receive News & Ratings for Antares Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.